Core Insights - The company, Kanglong Chemical, reported a revenue increase but a decline in net profit for the first half of 2025, with revenue reaching 6.441 billion yuan, a year-on-year growth of 14.93%, while net profit fell to 701 million yuan, a decrease of 37.0% [1] Financial Performance - The net profit margin decreased from 19.32% in the first half of 2024 to 10.13% in 2025, a drop of 9.19 percentage points, while the gross profit margin improved from 33.39% to 33.97% [3] - The return on equity (ROE) was 4.97%, down by 3.57 percentage points year-on-year [3] Operational Efficiency - The inventory turnover days were 51.25 days, a decrease of 1.81% compared to the first half of 2024, indicating improved inventory management efficiency [5] - The net cash flow from operating activities was 1.408 billion yuan, a year-on-year increase of 3.09% from 1.1 billion yuan in the same period of 2024 [5] - The asset-liability ratio for the first half of 2025 was 40.99%, an increase of 0.44 percentage points year-on-year [5] Institutional Holdings - As of the first half of 2025, the number of institutions holding Kanglong Chemical's stock decreased to 34, down by 315 from 349 in the same period of 2024, indicating a decline in investor confidence [8] - The company's market capitalization peaked at 194.307 billion yuan on August 5, 2021, and currently stands at 53.364 billion yuan, requiring a 264.12% increase in stock price to reach its historical high [8] - Despite the decline in market capitalization, the company retains growth potential due to its professional standing in the CRMO sector and the industry's development prospects [8]

Investment Rating - The investment rating for the company is "Buy" for both A and H shares [7]. Core Views - The company's performance in the first half of 2025 met expectations, with revenue of 6.441 billion yuan (up 14.9% year-on-year) and adjusted non-IFRS net profit of 756 million yuan (up 9.5% year-on-year) [1]. - The overall growth momentum remains strong, supported by a continuous increase in customer inquiries and new order amounts, which grew by over 10% year-on-year in the first half of 2025 [1]. - The report anticipates a favorable development for the company in 2025, driven by a recovering industry demand and the solid capabilities of its laboratory services [1]. Summary by Sections Financial Performance - In the first half of 2025, the company's gross margin was 34.0% (up 0.6 percentage points year-on-year), with significant contributions from core businesses such as laboratory services and CMC [2]. - The operating cash flow for the first half of 2025 was 1.408 billion yuan (up 28.1% year-on-year), indicating a positive trend in cash flow [2]. Laboratory Services - Revenue from the laboratory services segment in the first half of 2025 was 3.892 billion yuan (up 15.5% year-on-year), with biological sciences accounting for over 55% of the segment's revenue [3]. - The segment participated in 795 drug discovery projects (up 19.4% year-on-year) and saw new order amounts increase by over 10% [3]. - The company is enhancing its core business capabilities and applying AI technology, with the second Beijing park gradually coming into operation in the first half of 2025 [3]. Other Businesses - CMC business revenue in the first half of 2025 was 1.390 billion yuan (up 18.2% year-on-year), with a gross margin of 30.5% (up 2.2 percentage points) [4]. - The clinical CRO segment generated revenue of 939 million yuan (up 11.4% year-on-year), with a quarter-on-quarter increase of 10.0% in the second quarter of 2025 [4]. - The large molecule and CGT segment reported revenue of 211 million yuan (up 0.1% year-on-year), with a quarter-on-quarter increase of 14.3% in the second quarter of 2025 [4]. Profit Forecast and Valuation - The profit forecast remains unchanged, with expected net profits for 2025-2027 at 1.728 billion, 2.103 billion, and 2.507 billion yuan respectively [5]. - The company is assigned a target price of 39.83 yuan for A shares and 28.54 HKD for H shares, reflecting a PE ratio of 41x for A shares and 27x for H shares in 2025 [5].

格隆汇8月21日丨康龙化成(300759.SZ)公布2025年半年度报告，上半年公司实现营业收入64.41亿元，同 比增长14.93%；归属于上市公司股东的净利润7.01亿元，同比下降37.00%；归属于上市公司股东的扣除 非经常性损益的净利润6.37亿元，同比增长36.66%；基本每股收益0.3984元。 ...

Core Viewpoint - The report highlights the financial performance and operational developments of Pharmaron Beijing Co., Ltd. for the first half of 2025, showcasing growth in revenue and net profit while emphasizing the company's commitment to integrated drug research and development services across multiple therapeutic areas [1][4][21]. Financial Performance - The company reported a revenue of approximately 6.44 billion yuan, representing a 14.93% increase compared to the same period last year [3]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was approximately 636.66 million yuan, a 36.66% increase year-on-year [3]. - The basic earnings per share decreased by 36.58% to 0.3984 yuan, reflecting the impact of previous year's investment gains [3]. Business Operations - Pharmaron operates a comprehensive drug R&D service platform with 21 R&D centers and production bases globally, focusing on accelerating drug innovation [4]. - The company has strengthened its service capabilities in small molecule drugs, large molecule drugs, and cell and gene therapies, aiming to become a leading global player in multi-therapy drug development services [4][24]. - The laboratory services segment achieved revenue of approximately 389.25 million yuan, a 15.46% increase year-on-year, with a gross margin of 45.20% [7]. Client Engagement - The company served over 2,600 global clients, with 98.01% of revenue coming from existing clients [6]. - Revenue from the top 20 pharmaceutical clients increased by 47.98% year-on-year, accounting for 18.13% of total revenue [6]. - North American clients contributed 63.23% of total revenue, with a year-on-year growth of 11.02% [6]. Strategic Initiatives - The company is enhancing its digital and intelligent service capabilities, integrating AI technologies into various business areas to improve efficiency [17]. - A strategic partnership was established with Zhejiang University to create an AI Life Sciences Joint R&D Center, focusing on innovation in life sciences [6]. - Pharmaron is committed to sustainability, achieving 100% renewable electricity usage in some facilities and actively pursuing various international quality management certifications [6]. Industry Outlook - The global and Chinese pharmaceutical R&D and production markets are expected to maintain strong growth due to increasing healthcare investments and an aging population [21]. - The drug R&D outsourcing market is projected to grow rapidly, with integrated service platforms gaining market share as they help clients reduce costs and improve efficiency [22]. - The company is well-positioned to capitalize on these trends, leveraging its comprehensive service offerings to meet diverse client needs in drug development [24].

Core Viewpoint - 康龙化成 (Pharmaron) reported a decline in net profit for the first half of 2025, primarily due to the absence of significant investment gains seen in the previous year, despite an increase in revenue and cash flow from operations [2][6]. Financial Performance - The company's operating revenue for the reporting period was approximately 6.44 billion yuan, representing a year-on-year increase of 14.93% compared to 5.60 billion yuan in the same period last year [2]. - The net profit attributable to shareholders was approximately 701.40 million yuan, a decrease of 37.00% from 1.11 billion yuan in the previous year [2]. - The net cash flow from operating activities was approximately 1.41 billion yuan, an increase of 28.06% from 1.10 billion yuan in the previous year [2]. - Basic earnings per share were 0.3984 yuan, down 36.58% from 0.6282 yuan in the same period last year [2]. Company Overview - 康龙化成 is a leading integrated pharmaceutical R&D service platform with a global presence, focusing on accelerating drug innovation [5]. - The company operates 21 R&D centers and production bases across China, the UK, and the US, providing comprehensive drug research, development, and production services [5]. - The strategic focus is on a "full-process, integrated, international, and multi-therapy" approach to meet customer needs and enhance global operations [5]. Client and Revenue Breakdown - The company served over 2,600 global clients during the reporting period, with 98.01% of revenue coming from existing clients [6][7]. - Revenue from the top 20 pharmaceutical clients amounted to approximately 116.79 million yuan, a year-on-year increase of 47.98%, accounting for 18.13% of total revenue [7]. - Revenue from North American clients was approximately 407.26 million yuan, representing an 11.02% increase, while European clients contributed approximately 123.42 million yuan, a 30.52% increase [7]. Strategic Initiatives - The company is enhancing its digital and intelligent capabilities within its R&D service platform and has completed a controlling transaction with Zhejiang Haixin Zhihui Technology Co., Ltd. [6][7]. - A strategic cooperation agreement was signed with Zhejiang University to establish an AI Life Sciences Joint R&D Center, aimed at accelerating AI technology applications in life sciences [7]. - 康龙化成 is committed to sustainability, actively pursuing energy-saving initiatives and achieving 100% renewable electricity usage in some domestic parks [8]. ESG and Certifications - The company is expanding its ISO certification scope and has applied to join the United Nations Global Compact, committing to social responsibility in human rights, labor standards, and environmental practices [8]. - 康龙化成 received the "Industry Mover" title from S&P Global, reflecting recognition of its sustainable development efforts [8].

Group 1 - The board of directors of Kanglong Chemical held its 15th meeting on August 21, 2025, to discuss various proposals, including the approval of the 2025 semi-annual report and the decision not to distribute cash dividends for the year [1][2] - The board approved an additional investment of $10.5 million in the joint venture PharmaGend Global Medical Services Pte. Ltd. in Singapore, which is part of a $30 million financing round for infrastructure and operational expenses [3][4] - The board also approved adjustments to the stock incentive plans for 2021, 2022, and 2023, including changes to the grant prices due to capital adjustments [6][7] Group 2 - The company announced that the conditions for the fourth vesting period of the 2021 stock incentive plan have been met, allowing for the vesting of 329,331 shares, which will remain under lock-up until January 26, 2026 [8] - Similarly, the conditions for the third vesting period of the 2022 stock incentive plan have been met, allowing for the vesting of 681,766 shares, which will also remain under lock-up until January 27, 2026 [9] - The board approved the cancellation of unvested shares from the stock incentive plans for 2021, 2022, and 2023 due to the departure of certain incentive recipients [10][11] Group 3 - The company revised and added several governance policies to reduce compliance risks and meet EcoVadis and client evaluation requirements, including updates to training policies and sustainable procurement management [12]

Core Points - The company held its 13th meeting of the third Supervisory Board on August 21, 2025, via telecommunication, which complied with relevant laws and regulations [1] - The Supervisory Board approved the full semi-annual report for 2025, confirming its compliance with legal standards and accuracy [1][2] - The company plans to invest an additional $10.5 million in its joint venture in Singapore, PharmaGend Global Medical Services Pte. Ltd., to support infrastructure and operational needs [3][4] - The adjustments to the stock incentive plans for 2021, 2022, and 2023 were approved, ensuring compliance with relevant regulations and not harming shareholder interests [5][6] - The board confirmed that the conditions for the fourth vesting period of the 2021 stock incentive plan were met, but the stocks will remain unsold until January 26, 2026 [6] - The conditions for the third vesting period of the 2022 stock incentive plan were also met, with stocks remaining unsold until January 27, 2026 [7] - The board agreed to void unvested stocks from the 2021, 2022, and 2023 incentive plans due to the departure of certain employees and unmet performance targets [8][9]

| 元 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 占用方与上 | | 2025 年期初 | | 2025 年半年 | 2025 年半年 | 2025 年半年 | | | | | | 上市公司核算 | | 占用累计发生 | | | | 占用形成 | | | 非经营性资金占用 期末占用 | 资金占用方名称 | | 市公司的关 占用性质 | 占用资金余 | | | 度占用资金的 | 度偿还累计 | 度 | | | | 的会计科目 | | 金额（不含利 | | | | 原因 | | | | 联关系 | | 额 | | 利息（如有） | 发生金额 | 资金余额 | | | | | | | | 息） | | | | | | | 控股股东、实际控制人 | | | | | | | | | | | 及 | | | | | | | | 非经营性占用 | | | 其附属企业 | | | | | | | | | | | 非经营性占用 | | | | | | | | | | | - 小计 | - | - | ...

Group 1 - The company approved an investment in a joint venture, PharmaGend Global Medical Services Pte. Ltd., located in Singapore, with partners CMS Medical Venture Pte. Ltd., Rxilient Health Pte. Ltd., and Healthy Goal Limited [1][4] - The joint venture aims to raise $30 million through the issuance of 30 million Class A preferred shares, primarily for infrastructure and operational expenses [3][8] - The company plans to invest $10.5 million, corresponding to its 35% ownership in the joint venture, as part of the additional investment [2][8] Group 2 - The ownership structure of the joint venture post-investment will be as follows: the company will hold 32.38%, CMS Medical Venture will hold 31.27%, Rxilient Health will hold 10.36%, and Healthy Goal Limited will hold 18.50% [3][7] - The joint venture's financial data indicates total assets of $98.48 million and total liabilities of $40.32 million as of the latest reporting period [7][8] - The investment is expected to enhance the joint venture's capabilities in the Southeast Asian CDMO service market, contributing to the company's global and sustainable development [10][12] Group 3 - The investment transaction is classified as a related party transaction, with necessary approvals obtained from the board, excluding related directors from voting [4][10] - The company emphasizes that the additional investment will not alter its control over the joint venture or significantly impact its financial results [10][12] - The independent directors have reviewed the transaction and concluded that it will not harm the interests of the company or its shareholders, particularly minority shareholders [12]

上海妙道企业管理咨询有限公司 关于 康龙化成（北京）新药技术股份有限公司 第四个归属期归属条件成就相关事项 之 独立财务顾问报告 独立财务顾问： 二〇二五年八月 上海妙道企业管理咨询有限公司 独立财务顾问报告 一、董事会就本次激励计划设定的限制性股票归属条件是否成就的审议情况 .....10 二、本次归属条件成就之日和第四个归属期限制性股票继续禁售的说明 .........13 上海妙道企业管理咨询有限公司 独立财务顾问报告 第一章 声 明 上海妙道企业管理咨询有限公司接受委托，担任康龙化成（北京）新药技 术股份有限公司（以下简称"康龙化成""上市公司"或"公司"）2021 年 A 股限制性股票激励计划（以下简称"本激励计划"）的独立财务顾问（以下简 称"本独立财务顾问"），并制作本独立财务顾问报告。本独立财务顾问报告 是根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股权 激励管理办法》《深圳证券交易所创业板上市公司自律监管指南第 1 号——业 务办理》等法律、法规和规范性文件的有关规定，在康龙化成提供有关资料的 基础上，发表独立财务顾问意见，以供康龙化成全体股东及有关各方参考。 一、本独立财 ...